CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $2.13M, lower than 95% of all stocks globally
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
389.45BKRW280.62M · vs all stocks (USD)
Revenue (TTM)
2.95BKRW2.13M · vs all stocks (USD)
52-Week Change
115.10%vs all stocks
Market Capitalization
389.45BKRW280.62M · vs all stocks (USD)
Enterprise Value
381.52BKRW274.91M · vs all stocks (USD)
Price to Book (MRQ)
15.44xvs Biotechnology peers
Enterprise to Revenue
129.29xvs Biotechnology peers
Enterprise to EBITDA
-49.99xvs Biotechnology peers
Gross Margin
17.11%vs Biotechnology peers
Operating Margin
-301.58%vs Biotechnology peers
Return on Assets (TTM)
-28.38%vs Biotechnology peers
Return on Equity (TTM)
-31.76%vs Biotechnology peers
Revenue (TTM)
2.95BKRW2.13M · vs all stocks (USD)
Revenue per Share (TTM)
296.67KRWUpdated Aug 20, 2026Quarterly Revenue Growth
-50.90%vs Biotechnology peers
Gross Profit (TTM)
1.54BKRW1.11M · vs all stocks (USD)
EBITDA (TTM)
0.00KRWvs all stocks (USD)
Net Income (TTM)
-9.01BKRW-6.49M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-84.13%vs Biotechnology peers
Operating Cash Flow (TTM)
-8.07BKRW-5.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.01BKRW-6.49M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.95BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
1.41BKRWFY2025 · Dec 31, 2025Gross Profit
1.54BKRWFY2025 · Dec 31, 2025Operating Income
-11.37BKRW-8.19M · vs all stocks (USD)
Pre-tax Income
-9.01BKRWFY2025 · Dec 31, 2025Net Income
-9.01BKRWFY2025 · Dec 31, 2025EBIT
-8.90BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.63BKRWFY2025 · Dec 31, 2025Research & Development
7.42BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
2.04BKRWFY2025 · Dec 31, 2025Other Operating Expenses
145.78MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
441.08MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
112.67MKRWFY2025 · Dec 31, 2025EPS (Basic)
-906.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-906.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
9.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
9.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.01BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-9.34BKRWFY2025 · Dec 31, 2025Free Cash Flow
-10.43BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
8.79BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.01BKRWFY2025 · Dec 31, 2025Stock-based Compensation
350.78MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-328.41MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-42.12MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-313.17MKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.08BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-422.43MKRWFY2025 · Dec 31, 2025Purchase of Investments
-23.79BKRWFY2025 · Dec 31, 2025Sale of Investments
9.06BKRWFY2025 · Dec 31, 2025Other Investing Activity
242.89MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-15.57BKRWFY2025 · Dec 31, 2025Other Financing Charges
-7.94MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
21.31BKRWFY2025 · Dec 31, 2025Shares Outstanding
10.94MSharesUpdated Aug 20, 2026% Held by Insiders
22.82%vs all stocks
% Held by Institutions
12.12%vs all stocks
Total Cash (MRQ)
0.00KRWvs all stocks (USD)
Total Debt (MRQ)
798.20MKRW575.15K · vs all stocks (USD)
Current Ratio (MRQ)
15.79xvs Biotechnology peers
Book Value per Share (MRQ)
2.31KKRWUpdated Aug 20, 2026Total Assets
31.75BKRW22.88M · vs all stocks (USD)
Total Current Assets
27.05BKRWFY2025 · Dec 31, 2025Total Liabilities
3.38BKRWFY2025 · Dec 31, 2025Total Non-current Assets
4.71BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
1.59BKRWFY2025 · Dec 31, 2025Total Current Liabilities
1.79BKRWFY2025 · Dec 31, 2025Cash Equivalents
8.79BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
8.79BKRWFY2025 · Dec 31, 2025Other Short-term Investments
15.11BKRWFY2025 · Dec 31, 2025Accounts Receivable
1.24BKRWFY2025 · Dec 31, 2025Inventory
494.22MKRWFY2025 · Dec 31, 2025Accounts Payable
41.06MKRWFY2025 · Dec 31, 2025Short-term Debt
280.01MKRWFY2025 · Dec 31, 2025Other Current Liabilities
-80.00KRWFY2025 · Dec 31, 2025Long-term Debt
586.55MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
130.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
1.09BKRWFY2025 · Dec 31, 2025Retained Earnings
-72.91BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
28.37BKRW20.45M · vs all stocks (USD)
52-Week Low
14.20KKRWUpdated Aug 20, 202652-Week High
120.10KKRWUpdated Aug 20, 202652-Week Change
115.10%vs all stocks
50-Day MA
27.40KKRWUpdated Aug 20, 2026200-Day MA
61.83KKRWUpdated Aug 20, 2026Avg 10-Day Volume
140.65KSharesUpdated Aug 20, 2026Avg 30-Day Volume
84.52KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-906.00KRWUpdated Aug 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $2.13M, lower than 95% of all stocks globallySignificant
Revenue (USD): 2,126,313.719Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tomocube Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
OmniAb, Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nautilus Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Wave Life Sciences Ltd.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Sealsq Corp
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Enovix Corporation
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC